HEALTHCARE UTILIZATION IN OLDER ADULTS (≥70 YEARS) UNDERGOING CELLULAR THERAPY FOR HEMATOLOGIC MALIGNANCIES
Christina Snider(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), Harvey J. Murff(Brigham and Women's Hospital), Adetola A. Kassim(Vanderbilt University), Melissa Logue(Vanderbilt University Medical Center), Parul Goyal(Vanderbilt University Medical Center), Hina Budhwani(Vanderbilt University Medical Center), Kelly Pugh(Vanderbilt University Medical Center)
Cited by 0
Related Papers
Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer
|JAMA Oncology|2021|464
“I Wish I Had Seen This Test Result Earlier!”
|Archives of Internal Medicine|2004|299
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|282
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
|Journal of the National Comprehensive Cancer Network|2018|203
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2021|183